Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Oh on the Use of Abiraterone and Docetaxel in mCRPC

December 16th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel (Taxotere) in patients with metastatic castration-resistant prostate cancer.

Dr. Oh Discusses Choosing Abiraterone in Prostate Cancer

December 14th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Radium-223 Well Tolerated in Long-Term Safety Results in mCRPC

December 14th 2017

Three-year safety results from the ALSYMPCA trial showed that treatment with radium-223 dichloride (Xofigo) for men with mCRPC and symptomatic bone metastases was associated with minimal nonhematologic AEs.

Treatment Underuse in Prostate Cancer Rare, Disproportionately Affects Black Men

December 14th 2017

An analysis of racial disparities in prostate cancer treatment found that treatment underuse is rare, but when it does occur, it is almost exclusively in black men.

A Practice Model Designed to Reward Physician Partners Equally

December 14th 2017

Associated Medical Professionals of New York, a urology and radiation oncology practice, seeks to give its physician partners an equal share of its financial success while rewarding all staff members according to their levels of responsibility and workflow intensity.

Dr. Sweeney on Chemotherapy Versus Abiraterone for mCRPC

December 14th 2017

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the role of chemotherapy versus abiraterone (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Active Surveillance Underused in Prostate Cancer Patients Who Want to Preserve Sexual Function

December 13th 2017

In results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, 52.6% said that preserving sexual function was “very important,” but only 43.4% were assigned to active surveillance.

Dr. Graff Discusses Sipuleucel-T in Patients With mCRPC

December 8th 2017

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer.

Neoadjuvant Sonidegib Active in High-Risk Prostate Cancer

December 2nd 2017

In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.

Sensitivity, Resistance of Molecular Subtypes in Prostate Cancer Identified Through Drug Response Scores

December 2nd 2017

Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.

Radium-223/Abiraterone Phase III mCRPC Trial Unblinded

December 2nd 2017

The phase III ERA223 trial exploring radium-223 dichloride plus abiraterone acetate in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer has been unblinded early.

MRI, PCA3 Tests Are Reliable Indicators of Prostate Biopsy Positivity

December 1st 2017

Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.

Dr. Zhang on the ARCHES Trial in Prostate Cancer

December 1st 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

Radium-223 Retreatment Shows Promise in mCRPC

November 22nd 2017

A second course of radium-223 was associated with minimal hematologic toxicity and low radiographic bone progression rates in a phase I/II study of men with metastatic castration-resistant prostate cancer.

Challenges in mCRPC Landscape Surround Sequencing, Biomarkers, and PARP Inhibition

November 22nd 2017

Tanya B. Dorff, MD, discusses several important components regarding metastatic castration-resistant prostate cancer treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.

Dr. Berry on Novel Imaging Techniques for Prostate Cancer

November 22nd 2017

William R. Berry, MD, medical oncologist, Duke University, discusses novel imaging techniques for patients with prostate cancer.

EU Approves Abiraterone for Newly Diagnosed Hormone-Sensitive Prostate Cancer

November 22nd 2017

The European Commission has approved abiraterone acetate (Zytiga) in combination with prednisone/prednisolone for the treatment of adult men with newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer.

Expert Shares Insight on Role of RT, Surgery in Prostate Cancer

November 21st 2017

Jonathan Warner, MD, discusses the evolving role of surgery and radiation therapy in the treatment landscape for patients with prostate cancer.

Dr. Mason on the Significance of the PROTECT Study in Prostate Cancer

November 18th 2017

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

LDH a Predictor for OS in mCRPC Following Radium-223

November 18th 2017

Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.